Wikipedia -WSS

Wikipedia

author：explore 2025-09-30 19:25:26 - browse：22471

Illustration of a person walking across a tightrope, trying to balance. — Adobe

Hospitals are telling government officials it would be illegal to claw back $7.8 billion as part of a remedy that is making hospitals whole over underpaid drug discounts — and they may sue if that plan goes into effect.

The industry is walking a tightrope by trying to maximize the amount of money hospitals can keep. Lobbyists are praising federal officials for agreeing to dole out billions of dollars in future, lump-sum payments, but they are also pressuring Medicare not to offset a penny of those funds.

For several years during the Trump administration, Medicare cut payments for hospitals’ drugs under the federal 340B drug discount program, but the Supreme Court invalidated that policy in 2018. In July, Medicare proposed a solution: Hospitals would get $9 billion to cover what they are owed under the 340B program, but to offset those costs, the government would recoup $7.8 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Dario to buy mental health app maker Twill in cash and stock deal

WSS

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

A new nitrogen execution bill also undermines medical licensing

BMI, flaws aside, is found to be useful estimate of body fat in youth

R1 RCM gets $5.8 billion buyout offer from private equity firm

Let's speed up science by embracing open access publishing

NIH documents show early flaws of $1.6 billion long Covid program

hotspot

Wikipedia

entertainment

Psychedelics group wrestles with new pharma identity

Cord blood banking comes at a high cost to babies

Hepatitis C has a cure — but many Americans still lack access to it

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Novavax promises a turnaround & Lilly roils the obesity market

With competition flaring, obesity drug hits goal in liver disease study

DIEP, the 'gold standard' of breast reconstruction, is under threat

HIV drugs protect against transmission, even in unprotected sex

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

hotspot

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Alabama IVF ruling threatens families facing fatal genetic disease

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

PBM reform efforts get punted in Congress

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

explore

leisure time

knowledge

knowledge